| Bernard Armah, | |
|
693 Bloomfield Ave Ste 401, Bloomfield, CT 06002-2489 | |
| (860) 731-5522 | |
| (860) 731-5536 |
| Full Name | Bernard Armah |
|---|---|
| Gender | Male |
| Speciality | Licensed Practical Nurse |
| Location | 693 Bloomfield Ave Ste 401, Bloomfield, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003419730 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 036979 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Bernard Armah, 2 Waterside Xing Ste 401, Windsor, CT 06095-1588 Ph: (860) 731-5522 | Bernard Armah, 693 Bloomfield Ave Ste 401, Bloomfield, CT 06002-2489 Ph: (860) 731-5522 |
News Archive
EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
The research team led by Masakazu Ohara, graduate student of the Department of Computer Science and Engineering at Toyohashi University of Technology (student in the Leading Program doctoral program); Associate Professor Kowa Koida of the Electronics-Inspired Interdisciplinary Research Institute; and Associate Professor Juno Kim of the University of New South Wales (Australia) discovered that when people judge the thickness of an object, objects with glass-like transparent optical properties are perceived to be flatter than they actually are.
A new paper published on the preprint server medRxiv* in May 2020 reports the first evidence that vitamin D deficiency and inadequate treatment could increase the chances of testing positive for COVID-19. This could shape the way for screening individuals at risk for vitamin D deficiency.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor (HGF) antibody candidate.
› Verified 2 days ago
Mandy Marie Boehnert, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 200 Seabury Dr, Bloomfield, CT 06002 Phone: 860-243-4022 |